Afficher la notice

dc.contributor.authorNguyen, Mimosa
dc.contributor.authorMukaneza, Yvette
dc.contributor.authorTremblay, Mélanie
dc.contributor.authorHuard, Geneviève
dc.contributor.authorTang, An
dc.contributor.authorRose, Christopher
dc.contributor.authorBémeur, Chantal
dc.date.accessioned2022-05-10T12:27:45Z
dc.date.availableNO_RESTRICTIONfr
dc.date.available2022-05-10T12:27:45Z
dc.date.issued2022-05-02
dc.identifier.urihttp://hdl.handle.net/1866/26643
dc.publisherUniversity of Toronto Pressfr
dc.subjectCirrhosisfr
dc.subjectLiver transplantationfr
dc.subjectRenal dysfunctionfr
dc.subjectSarcopeniafr
dc.titleRenal dysfunction independently predicts muscle mass loss in patients following liver transplantationfr
dc.typeArticlefr
dc.contributor.affiliationUniversité de Montréal. Faculté de médecine. Département de médecinefr
dc.contributor.affiliationUniversité de Montréal. Faculté de médecine. Département de nutritionfr
dc.contributor.affiliationUniversité de Montréal. Faculté de médecine. Département de radiologie, radio-oncologie et médecine nucléairefr
dc.identifier.doi10.3138/canlivj-2021-0042
dcterms.abstractLiver transplantation (LT) is the only curative treatment for cirrhosis. However, the presence of complications can impact outcomes following LT. Sarcopenia, or muscle mass loss, is highly prevalent in patients with cirrhosis and is associated with longer hospitalization stays and a higher infection rate post-surgery. We aimed to identify patients at higher risk of early sarcopenia post-LT. METHODS: This retrospective study included 79 cirrhotic patients who underwent LT. Muscle mass was evaluated using the third lumbar spine vertebra skeletal muscle mass index (SMI) and sarcopenia was defined using established cut-off values. Computerized tomography (CT) scans performed within six-month peri-operative period (three months pre- and post-LT) were included in the study. Complications and comorbidities were collected and correlated to SMI post-LT and predictive models for SMI post-LT were constructed. RESULTS: The overall prevalence of sarcopenia was 46% and 62% before and after LT, respectively. Newly developed sarcopenia was found in 42% of patients. Post-LT sarcopenia was associated with longer hospital stays (54±37 vs 29±10 days, p = 0.002), higher number of infection (3±1 vs 1±2, p = 0.027), and greater number of complications (5±2 vs 3±2, p <0.001) compared to absence of sarcopenia. Multivariate analyses showed that the SMI post-LT was independently associated with pre-LT renal function markers, the glomerular filtration rate (GFR) and creatinine (Model 1, GFR: β = 0.33; 95% CI = 0.04–0.17; p = 0.003; Model 2, Creatinine: β = –0.29; 95% CI = –0.10 to –0.02; p = 0.009). CONCLUSIONS: The present study highlights the potential role of renal dysfunction in the development and persistence of sarcopenia after LT.fr
dcterms.isPartOfurn:ISSN:2561-4444fr
dcterms.languageengfr
UdeM.ReferenceFournieParDeposant10.3138/canlivj-2021-0042fr
UdeM.VersionRioxxVersion acceptée / Accepted Manuscriptfr
oaire.citationTitleCanadian liver journalfr


Fichier·s constituant ce document

Vignette

Ce document figure dans la ou les collections suivantes

Afficher la notice

Ce document diffusé sur Papyrus est la propriété exclusive des titulaires des droits d'auteur et est protégé par la Loi sur le droit d'auteur (L.R.C. (1985), ch. C-42). Il peut être utilisé dans le cadre d'une utilisation équitable et non commerciale, à des fins d'étude privée ou de recherche, de critique ou de compte-rendu comme le prévoit la Loi. Pour toute autre utilisation, une autorisation écrite des titulaires des droits d'auteur sera nécessaire.